Palisade Bio receives notice of allowance for patent of PALI-2108 in China

Palisade Bio (PALI) announced that the China National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108, the Company’s novel, locally-activated, terminal ileum and colon-targeted phosphodiesterase-4 B/D inhibitor being developed for fibrostenotic Crohn’s disease, FSCD, and moderate to severe ulcerative colitis. Once issued, the allowed patent titled, “Gut Microbiota-Activated PDE4 Inhibitor Prodrug,” will cover claims on the composition of matter for PALI-2108 in China with a base patent term currently extending into 2045, subject to extension to account for time required to fulfill requirements for regulatory approval.